Reno, Nevada (UroToday.com) -- Bayer will present new oncology data, including a late-breaking, comprehensive analysis from the Phase III ARANOTE trial investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17, 2024.
ESMO 2024: BL-B01D1-201: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Dingwei Ye discussing BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma.